Leveraging innovations in plasmid manufacturing to bring advanced therapies to market


Recent increases in commercial utilizations for plasmid DNA have triggered the need for increased capacity as well as clarity on appropriate application of regulatory guidance and GMP principles in the manufacturing process. Download this whitepaper for insights on market trends influencing the supply of pDNA for advanced therapies, as well as manufacturing strategies to help accelerate timelines, mitigate risk and optimize clinical outcomes.